Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparativein vitroactivity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci

29 Sept 2016

Abstract excerpt

Sir, Antibiotic research has focused on discovering agents with activity against MDR pathogens (e.g. ESKAPE pathogens1), including VRE, which along with Staphylococcusaureus are commonly isolated from healthcare-associated infections.2 Several new agents have been approved for the treatment of skin and skin structure infections caused by MRSA and enterococci, including oxazolidinones (linezolid and tedizolid),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotics Pharmacokinetics and Efficacy
Share to Antimicrobial Resistance in Staphylococcus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27856721
DOI: 10.1093/jac/dkw451

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparativein vitroactivity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococciPMID 27856721Read ↗

Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013–2014)Semantic proximity Read ↗

Optimizing Therapy for Vancomycin-Resistant Enterococci (VRE)Semantic proximity Read ↗

Oritavancin Activity against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci with Molecularly Characterized Glycopeptide Resistance Genes Recovered from Bacteremic Patients, 2009-2010Semantic proximity Read ↗

From Vancomycin to Oritavancin: The Discovery and Development of a Novel Lipoglycopeptide AntibioticSemantic proximity Read ↗

New Gram-Positive Agents: the Next Generation of Oxazolidinones and LipoglycopeptidesSemantic proximity Read ↗

In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).Semantic proximity Read ↗

Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensSemantic proximity Read ↗

In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections.Semantic proximity Read ↗

Bactericidal Activity and Resistance Development Profiling of DalbavancinSemantic proximity Read ↗

Comparative time-kill study of doxycycline, tigecycline, cefazolin and vancomycin against several clones of Staphylococcus aureus.Semantic proximity Read ↗

Comparison of agar dilution, broth microdilution, E-test, disk diffusion, and automated Vitek methods for testing susceptibilities of Enterococcus spp. to vancomycin.Semantic proximity Read ↗

In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.